



**Caprolactam Chemicals Limited**  
CIN No. L24110MH1988PLC049683

**STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025**

PART I		(Rs. In Lakhs)				
	PARTICULARS	Quarter Ended			Year Ended	Year Ended
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
		31-03-2025	31-12-2024	31-03-2024	31-03-2025	31-03-2024
<b>1</b>	<b>Revenue From Operation</b>					
	Revenue from Operations	160.85	229.38	143.65	673.96	695.73
	Other Income	0.17	0.58	2.88	0.96	17.98
	<b>Total Income</b>	<b>161.02</b>	<b>229.96</b>	<b>146.54</b>	<b>674.92</b>	<b>713.71</b>
<b>2</b>	<b>Expenses</b>					
(a)	Cost of materials consumed	(27.67)	48.93	5.13	53.22	48.77
(b)	Purchase of stock - In trade	38.94	7.49	-	84.64	-
(c)	Change in inventories of Finished goods, work-in-progress and stock intrade	-	11.82	-	(3.75)	-
(d)	Employee benefits expenses	10.21	8.04	10.46	37.09	38.75
(e)	Finance Costs	17.61	16.83	12.05	62.86	49.78
(f)	Depreciation, depletion and amortisation expenses	41.23	40.36	41.51	158.85	158.22
(g)	Other expenses	116.65	105.83	60.85	350.38	390.94
	<b>Total Expenses</b>	<b>196.97</b>	<b>239.30</b>	<b>130.00</b>	<b>743.29</b>	<b>686.47</b>
<b>3</b>	<b>Profit / (Loss) before tax (1-2)</b>	<b>(35.96)</b>	<b>(9.34)</b>	<b>16.54</b>	<b>(68.37)</b>	<b>27.24</b>
<b>4</b>	<b>Tax Expense</b>					
	Current tax	-	-	2.97	-	4.75
	Deferred tax	9.11	(6.17)	1.83	2.50	2.75
	<b>Total Tax Expenses</b>	<b>9.11</b>	<b>(6.17)</b>	<b>4.80</b>	<b>2.50</b>	<b>7.50</b>
<b>5</b>	<b>Total Profit/(loss) After Tax (3-4)</b>	<b>(45.07)</b>	<b>(3.17)</b>	<b>11.74</b>	<b>(70.87)</b>	<b>19.74</b>
<b>6</b>	<b>Other Comprehensive Income (OCI)</b>					
a)	Items That Will Not Be Reclassified To Profit or Loss	(0.96)		0.72	(0.96)	0.72
b)	Items That Will Be Reclassified To Profit or Loss			0.08		0.08
<b>7</b>	<b>Total Comprehensive Income/(Loss) for the period (5+6)</b>	<b>(46.03)</b>	<b>(3.17)</b>	<b>12.54</b>	<b>(71.83)</b>	<b>20.54</b>
<b>8</b>	<b>Details of equity share capital</b>					
9	Paid-up equity share capital	460.00	460.00	460.00	460.00	460.00
	Face value of equity share capital	10.00	10.00	10.00	10.00	10.00
<b>10</b>	<b>Other Equity</b>					
<b>11</b>	<b>Earnings per share</b>					
<b>12</b>	<b>Earnings per equity share Rs.</b>					
	Basic	(0.98)	(0.07)	0.26	(1.54)	0.43
	Diluted	(0.98)	(0.07)	0.26	(1.54)	0.43
<b>13</b>	<b>Nominal value of share</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>	<b>10.00</b>
<b>Disclosure of notes on finance results</b>						
1. The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30th May, 2025 and have been subjected to limited review by the Auditors.						
2) These financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.						
3) The Standalone results of the compnay are available on the company's website <a href="http://caprolactam.co.in/">http://caprolactam.co.in/</a> and also available on the websites of the BSE Ltd. And National Stock Exchange of India Ltd.						
4) Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary. Figures for the previous quarter/ period have been regrouped/reclassified, wherever considered necessary.						
5) The figures in Rs. Lakhs are rounded off to Two Decimals						
Place: Mahad		FOR AND BEHALF OF THE BOARD OF DIRECTORS				
Date: 30.05.2025		Mrs. Zaver S Bhanushali				
		  Managing Director DIN- 00663374				

**CAPROLACTAM CHEMICALS LIMITED**  
CIN No. L24110MH1988PLC049683

( Amount in lakhs)

Standalone Statement of Assets and Liabilities		Period ended As at	Period ended As at
Particulars		31-03-2025 Audited	31-Mar-24 Audited
<b>I</b>	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
	Property, plant and equipment	1,030.54	1,029.07
	Right to use of Assets	0.92	-
	Capital work-in-progress	-	-
	Financial assets	-	-
	i. Other Financial Assets	30.93	30.53
	<b>Total non-current assets</b>	<b>1,062.39</b>	<b>1,059.60</b>
2	<b>Current assets</b>		
	Inventories	40.65	6.70
	Trade receivables	282.42	63.66
	Cash and cash equivalents	8.37	8.65
	Other current financial assets	34.59	26.77
	<b>Total Current financial assets</b>	<b>366.03</b>	<b>105.77</b>
	<b>Total assets</b>	<b>1,428.42</b>	<b>1,165.37</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Equity</b>		
	Equity share capital	460.00	460.00
	Other equity	22.85	94.71
	<b>Total equity attributable to owners of parent</b>	<b>482.85</b>	<b>554.71</b>
	<b>Total equity</b>	<b>482.85</b>	<b>554.71</b>
2	<b>Liabilities</b>		
	<b>Non-current liabilities</b>		
	<b>Non-current financial liabilities</b>		
	Borrowings, non-current		
	Deferred tax liabilities (net)	6.42	3.92
	<b>Total non-current liabilities</b>	<b>6.42</b>	<b>3.92</b>
	<b>Current liabilities</b>		
	<b>Current financial liabilities</b>		
	Borrowings, current	871.34	586.27
	Trade payables, current	43.77	15.16
	Other current financial liabilities	18.07	1.57
	Employee Benefit obligation	5.97	3.75
	<b>Total current financial liabilities</b>	<b>939.15</b>	<b>606.74</b>
	<b>Total current liabilities</b>	<b>939.15</b>	<b>606.74</b>
	<b>Total L liabilities</b>	<b>945.57</b>	<b>610.66</b>
	<b>Total equity and liabilities</b>	<b>1,428.42</b>	<b>1,165.37</b>
<b>Disclosure of notes on assets and liabilities</b>			
1. The results of the quarter & year ended 31 March, 2025 were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 30/05/2025.			
2. Previous Year Figures have been regrouped wherever necessary.			
Place: Mahad			
Date: 30/05/2025			



Revised

**CAPROLACTAM CHEMICALS LIMITED**

**CIN No. L24110MH1988PLC049683**

**Cash Flow Statement for the period ended 31.03.2025**

**( Amount in lakhs)**

<b>Particulars</b>	<b>Period ended As at 31 March 2025</b>	<b>Period ended As at 31 March 2024</b>
<b>CASH FLOW FROM OPERATING ACTIVITIES:</b>		
Net Profit before tax as per Statement of Profit and Loss	(68.37)	27.24
Adjustment for:		
Depreciation/ Amortisation	158.85	158.22
Interest Expenses	62.86	49.78
Interest Income	(0.96)	(0.80)
<b>Operating Profit before Working Capital Changes</b>	<b>152.39</b>	<b>234.45</b>
Adjusted for :		
(Increase)/Decrease in non-current financial assets	(0.40)	(19.58)
(Increase)/Decrease in Inventories	(33.96)	2.06
(Increase)/Decrease in Trade Receivables	(218.76)	3.92
(Increase)/Decrease in Other Current Assets	(7.59)	(4.21)
Increase/(Decrease) in Trade Payables	28.61	(13.75)
Increase/(Decrease) in Current Financial Liabilities	16.51	(13.99)
Increase/(Decrease) in Employee benefit obligation & other liabilities	1.26	1.07
	(214.33)	(44.48)
Cash Generated from Operations	<b>(61.94)</b>	<b>189.97</b>
Taxes refund / (paid) - (net)	(0.26)	(7.72)
<b>Net Cash from/(used in) Operating Activities (A)</b>	<b>(62.20)</b>	<b>182.24</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES:</b>		
Purchase of Fixed Assets	(161.25)	(165.22)
Interest Received	0.96	0.80
<b>Net Cash from Investing Activities (B)</b>	<b>(160.29)</b>	<b>(164.42)</b>
<b>CASH FLOW FROM FINANCING ACTIVITIES:</b>		
Long term borrowings	-	-
Short Term Borrowings	285.08	17.51
Interest Paid	(62.86)	(49.78)
<b>Net Cash from Financing Activities (C)</b>	<b>222.22</b>	<b>(32.27)</b>
<b>Net cash and cash equivalents (A + B + C)</b>	<b>(0.28)</b>	<b>(14.44)</b>
<b>Cash and cash equivalents at beginning of the period</b>	<b>8.65</b>	<b>23.09</b>
<b>Cash and cash equivalents at end of the period</b>	<b>8.37</b>	<b>8.65</b>

**Notes:-**

1. Cash flow statement has been prepared under Indirect method as set out in Ind AS 7 as per the Companies (Indian Accounting Standards) Rule 2015 as ammended by the Companies (Indian Accounting Standards) (Amendment) Rule, 2016.

2. Previous years figures have been restated and regrouped wherever necessary.

3. Figures in bracket indicates cash outflow .

4. Components of cash and cash equivalents at the year end comprise of

Date:- 30/05/2025

Place :- Mahad



*[Handwritten Signature]*

Date: 04.06.2025

**The Deputy Manager,**  
Department of Corporate Services,  
**BSE Limited,**  
P.J. Towers, Dalal Street, Fort,  
Mumbai - 400001.

**Scrip Code: 507486 (BSE)**

**Subject: Submission of Revised Financial Statement of the Quarter and Financial Year ended 31<sup>st</sup> March, 2025**

Dear Sir(s),

With reference to the above captioned subject and pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we would like to submit the revised Financial Results of the Company along with the Statement of Assets and Liabilities, Statement of Cash Flow and Audit Report, as there were some minor clerical error in the Audited Financial Results of the Company which was noticed after filing for the Quarter and Financial Year ended 31st March, 2025.


Please be apprised that these results have already been approved by the Board of Directors in the meeting held on 30th May, 2025 which commenced at 04:00 P.M and concluded at 06:00 P.M.

This is for the information of members.

Thanking you,

Yours Faithfully,

**For Caprolactam Chemical Limited**



Zaver Shankarlal Bhanushali  
Managing Director  
DIN: 00663374

